Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States

JAMA Oncol. 2017 May 1;3(5):705-707. doi: 10.1001/jamaoncol.2016.5465.

Authors

Jim C Hu¹, Paul Nguyen², Jialin Mao³, Joshua Halpern¹, Jonathan Shoag¹, Jason D Wright⁴, Art Sedrakyan³

Affiliations

¹ Department of Urology, Weill Cornell Medicine-New York Presbyterian Hospital, New York.
² Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts.
³ Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, New York.
⁴ Department of Gynecology, Columbia College of Physicians and Surgeons, New York, New York.

Abstract

This population-based study assesses the effect of the decline in prostate-specific antigen screening and incidence on prostate cancer presentation.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Humans
Kallikreins / blood
Male
Prostate-Specific Antigen / blood
Prostatic Neoplasms / diagnosis*
Prostatic Neoplasms / epidemiology
Prostatic Neoplasms / pathology*
SEER Program
United States / epidemiology

Substances

KLK3 protein, human
Kallikreins
Prostate-Specific Antigen